文献速递艾滋病与性传播感染

印度高危人群HIV暴露前预防与检测策略的成本效果

The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该研究用印度数据构建HIV微模拟模型,比较男男性行为者(MSM)和注射吸毒者(PWID)的7种检测与暴露前预防(PrEP)策略。结果显示PrEP联合每6个月检测对MSM(ICER 1000美元/年挽救生命)和PWID(ICER 500美元/年挽救生命)均具成本效果。

要点

  • PrEP联合每6个月检测对印度MSM和PWID均具成本效果。
  • 单独HIV检测可延长MSM寿命0.07–0.30年,PrEP额外增加约0.90生命年。

核心结论

  • PrEP联合每6个月检测是印度MSM和PWID具成本效果的HIV预防策略。
  • 结果对HIV发病率最敏感,高发病率地区可优先扩大PrEP。

研究设计与样本

  • 采用印度特异性数据填充HIV微模拟模型,投影7种策略的临床与经济结局。
  • 策略包括现状、一次性HIV检测、每3/6/12个月常规检测、PrEP联合每3或6个月检测。
  • 成本效果阈值定义为1950美元(2017年印度人均GDP)。

主要发现

  • 单独HIV检测使MSM预期寿命增加0.07–0.30年,PrEP较现状增加约0.90生命年。
  • PWID结果与MSM相似。
  • PrEP联合6个月检测对MSM的ICER为1000美元/年挽救生命,对PWID为500美元/年挽救生命。

关键数值与推荐

  • 成本效果阈值:1950美元(2017年印度人均GDP)。
  • PrEP联合6个月检测:MSM ICER 1000美元/年挽救生命,PWID ICER 500美元/年挽救生命。

临床怎么用

  • 对印度MSM和PWID可考虑采用PrEP联合每6个月HIV检测作为成本效果策略。
  • 全国推广需大量财政投入,可优先在高HIV发病率地区扩大PrEP。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The human immunodeficiency virus (HIV) epidemic in India is concentrated among 3.1 million men who have sex with men (MSM) and 1.1 million people who inject drugs (PWID), with a mean incidence of 0.9-1.4 per 100 person-years. We examined the cost-effectiveness of both preexposure prophylaxis (PrEP) and HIV testing strategies for MSM and PWID in India. METHODS: We populated an HIV microsimulation model with India-specific data and projected clinical and economic outcomes of 7 strategies for MSM/PWID, including status quo; a 1-time HIV test; routine HIV testing every 3, 6, or 12 months; and PrEP with HIV testing every 3 or 6 months. We used a willingness-to-pay threshold of US$1950, the 2017 Indian per capita gross domestic product, to define cost-effectiveness. RESULTS: HIV testing alone increased life expectancy by 0.07-0.30 years in MSM; PrEP added approximately 0.90 life-years to status quo. Results were similar in PWID. PrEP with 6-month testing was cost-effective for both MSM (incremental cost-effectiveness ratio [ICER], $1000/year of life saved [YLS]) and PWID (ICER, $500/YLS). Results were most sensitive to HIV incidence. PrEP with 6-month testing would increase HIV-related expenditures by US$708 million (MSM) and US$218 million (PWID) over 5 years compared to status quo. CONCLUSIONS: While the World Health Organization recommends PrEP with quarterly HIV testing, our analysis identifies PrEP with semiannual testing as the cost-effective HIV prevention strategy for Indian MSM and PWID. Since nationwide scale-up would require a substantial fiscal investment, areas of highest HIV incidence may be the appropriate initial targets for PrEP scale-up.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kazemian P, Costantini S, Kumarasamy N, et al. The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India. Clin Infect Dis. 2020. PMID: 30921454. doi:10.1093/cid/ciz249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。